ReWalk Robotics announced that the Centers for Medicare & Medicaid Services has officially revised its April 2024 Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Fee Schedule to include a final lump-sum Medicare purchase fee schedule amount for personal exoskeletons with a ceiling-to-floor range from $109,238 to $81,929, and an established rate of $91,032 for each state. CMS states that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers. The finalization of the payment level follows the previous determination by CMS through rulemaking that personal exoskeletons such as the ReWalk Personal Exoskeleton fall within the brace benefit category, which is reimbursed by Medicare on a lump sum basis. The final payment determination was made by CMS through a “gap filling” process after CMS determined that lower extremity exoskeletons incorporate “revolutionary features” that cannot be described by any existing code or combination of codes. The final payment rate is in effective for Medicare claims with dates of service on or after April 1, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Rewalk Robotics Clarifies Regulatory Disclosure Standards
- Lifeward CEO updates shareholders on Exoskeleton and Medicare progress
- Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
- ReWalk Robotics applauds introduction of VA STAND act in U.S. Senate
- VA STAND Act introduced in the United States Senate